تفاصيل الوثيقة

نوع الوثيقة : مقال في مجلة دورية 
عنوان الوثيقة :
Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
 
لغة الوثيقة : الانجليزية 
المستخلص : Background: Her2/neu is an oncogene that plays an important role in the pathogenesis of many cancer types. In bladder carcinoma (BC), the clinical significance of Her2/neu status remains under-investigated and poorly linked to the patients’ clinic-pathological features and survival status. Thus, the current study was conducted to assess Her2/ neu status in a cohort of patients’ in Saudi Arabia, and to explore its prognostic value in BC. Methods: A total of 160 consent patients of transitional cell carcinoma (TCC) of bladder were arranged on a tissue microarray (TMA) and stained by immunohistochemistry (IHC) and bright-field dual in situ hybridization (BDISH) methods. The intensity of Her2/neu protein receptor immunostaining was evaluated, correlated to Her2/neu gene amplification status in TCC and assessed for potential clinical value by correlation measures. Results: IHC data demonstrated that Her2/neu protein is expressed in 60 % (2+ and 3+) of our TCC patient’s cohort from Saudi Arabia. Her2/neu gene amplification is detected in 25 % by BDISH. There was a strong association between Her2/neu protein levels and lymph node invasion (p = 0.04), tumor stage (p = 0.002), vascular invasion and borderline significance with distant metastasis (p = 0.07). Amplification of Her2/neu gene was associated with tumor grade (p = 0.03) and poor disease-specific survival (p = 0.02), in that, patients with non-amplified Her2/neu gene live longer. Interestingly, there was a reasonable concordance rate (71 %) between IHC and BDISH data in the analyzed cohort. Conclusion: The study showed that 25 % of our patients’ cohort has Her2/neu over-expression. This Her2/neu (over-expression/amplification) status was concordant using either IHC or BDISH and significantly associated with disease aggressiveness and poor outcome. These findings suggested a potential impact of anti-Her2 targeted therapy in the treatment of bladder cancer with amplified/overexpressed HER2 that needs further investigation. 
ردمد : 1471-2407 
اسم الدورية : BMC cancer 
المجلد : 16 
العدد : 1 
سنة النشر : 1437 هـ
2016 م 
نوع المقالة : مقالة علمية 
تاريخ الاضافة على الموقع : Tuesday, July 18, 2017 

الباحثون

اسم الباحث (عربي)اسم الباحث (انجليزي)نوع الباحثالمرتبة العلميةالبريد الالكتروني
Taoufik NedjadiNedjadi, Taoufik باحثدكتوراه 
Jaudah Al-MaghrabiAl-Maghrabi, Jaudah باحثدكتوراه 
Mourad AssidiAssidi, Mourad باحثدكتوراه 
Ashraf DallolDallol, Ashraf باحثدكتوراه 
Heba Al-KattabiAl-Kattabi, Heba باحثدكتوراه 
Adeel ChaudharyChaudhary, Adeel باحثدكتوراه 
Ahmed Al-SayyadAl-Sayyad, Ahmed باحثدكتوراه 
Adel Al-AmmariAl-Ammari, Adel باحثدكتوراه 
Adel AbuzenadahAbuzenadah, Adel باحثدكتوراه 
Abdelbaset BuhmeidaBuhmeida, Abdelbaset باحثدكتوراه 
Mohammed Al-QahtaniAl-Qahtani, Mohammed باحثدكتوراه 

الملفات

اسم الملفالنوعالوصف
 42088.pdf pdf 

الرجوع إلى صفحة الأبحاث